Abstract
This double-blind study investigated the efficacy and safety of rapid-acting intramuscular olanzapine in treating agitation associated with Alzheimer's disease and/or vascular dementia. At 2 h, olanzapine (5.0 mg, 2.5 mg) and lorazepam (1.0 mg) showed significant improvement over placebo on the PANSS Excited Component (PANSS-EC) and Agitation–Calmness Evaluation Scale (ACES), and both 5.0 mg olanzapine and lorazepam showed superiority to placebo on the Cohen-Mansfield Agitation Inventory. At 24 h, both olanzapine groups maintained superiority over placebo on the PANSS-EC; lorazepam did not. Olanzapine (5.0 mg) and lorazepam improved ACES scores more than placebo. Simpson–Angus and Mini-Mental State Examination scores did not change significantly from baseline. Sedation (ACES ⩾8), adverse events, and laboratory analytes were not significantly different from placebo for any treatment. No significant differences among treatment groups were seen in extrapyramidal symptoms or in corrected QT interval at either 2 h or 24 h, and no significant differences among treatment groups were seen in vital signs, including orthostasis. Intramuscular injection of olanzapine may therefore provide substantial benefit in rapidly treating inpatients with acute dementia-related agitation.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
American Psychiatric Association. (1994): Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC, American Psychiatric Association
Auchus AP, Bissey-Black C . (1997): Pilot study of haloperidol, fluoxetine, and placebo in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 9: 591–593
Barclay AM . (1985): Psychotropic drugs in the elderly: selection of the appropriate agent. Postgrad Med 77: 153–157160–162
Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, Dubin W, McGlynn C, Goodman L . (1997): Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am J Emerg Med 15: 335–340
Bianchetti G, Zarifian E, Poirier-Littre MF, Morselli PL, Deniker P . (1980): Influence of route of administration on haloperidol plasma levels in psychotic patients. Int J Clin Pharmacol Ther Toxicol 18: 324–327
Caligiuri MP, Lacro JP, Jeste DV . (1999): Incidence and predictors of drug-induced parkinsonism in older psychiatric patients treated with very low doses of neuroleptics. J Clin Psychopharmacol 19: 322–328
Campbell H, Crawford V, Stout RW . (1990): The impact of private residential and nursing care on statutory residential and hospital care of elderly people in south Belfast. Age Ageing 19: 318–324
Clark WS, Street JS, Feldman PD, Breier A . (2001): The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. J Clin Psychiatry 62: 34–40
Class CA, Schneider L, Farlow MR . (1997): Optimal management of behavioural disorders associated with dementia. Drugs Aging 10: 95–106
Cohen-Mansfield J . (1986): Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated. J Am Geriatr Soc 34: 722–727
Cohen-Mansfield J, Billig N, Lipson S, Rosenthal AS, Pawlson LG . (1990): Medical correlates of agitation in nursing home residents. Gerontology 36: 150–158
De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PLJ, Eriksson S, Lawlor BA . (1999): A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53: 946–955
Deutsch LH, Rovner BW . (1991): Agitation and other noncognitive abnormalities in Alzheimer's disease. Psychiatr Clin North Am 14: 341–351
Devanand DP, Levy SR . (1995): Neuroleptic treatment of agitation and psychosis in dementia. J Geriatr Psychiatry Neurol 8 (suppl 1):S18–S27
Dubin WR, Waxman HM, Weiss KJ, Ramchandani D, Tavani-Petrone C . (1985): Rapid tranquilization: the efficacy of oral concentrate. J Clin Psychiatry 46: 475–478
Expert Consensus Guideline Series. (1998): Treatment of agitation in older persons with dementia. In Alexopoulos GS, Silver JM, Kahn DA, Frances A, Carpenter D (eds), The Expert Consensus Guideline Series: Agitation in Older Persons with Dementia. New York, McGraw-Hill Publishing, Inc., pp 1–88
Folstein MF, Folstein SE, McHugh PR . (1975): Mini-Mental State. A practical method for grading the cognitive state of patients by the clinician. J Psychiatr Res 12: 189–198
Foster S, Kessel J, Berman ME, Simpson GM . (1997): Efficacy of lorazepam and haloperidol for rapid tranquilization in a psychiatric emergency room setting. Int Clin Psychopharmacol 12: 175–179
Gillings D, Koch G . (1991): The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Info J 25: 411–425
Girling DM, Berrios GE . (1990): Extrapyramidal signs, primitive reflexes and frontal lobe function in senile dementia of the Alzheimer type. Br J Psychiatry 157: 888–893
Greenblatt DJ, Divoll M . (1983): Diazepam versus lorazepam: relationship of drug distribution to duration of clinical action. Adv Neurol 34: 487–491
Gurland BJ, Cross PS . (1982): Epidemiology of psychopathology in old age: some implications for clinical services. Psychiatr Clin North Am 5: 11–26
Guy W . (1976):ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, Md, US Department of Health, Education, and Welfare
Kahn J-P, Yisak W, Albaret C, Nilsson L, Zaar-Hedin A, Laxenaire M . (1990): Tolerability and pharmacokinetics of remoxipride after intramuscular administration. Acta Psychiat Scand 82 (suppl 358):51–53
Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M . (1999): Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 60: 107–115
Kay S, Opler L, Fiszbein A . (1986): Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY, Multi-Health Systems
Kay SR, Sevy S . (1990): Pyramidical model of schizophrenia. Schizophr Bull 16: 537–545
Kunik ME, Yudofsky SC, Silver JM, Hales RE . (1994): Pharmacologic approach to management of agitation associated with dementia. J Clin Psychiatry 55 (suppl):13–17
Lancon C, Auquier P, Nayt G, Reine G . (2000): Stability of the five-factor structure of the Positive and Negative Syndrome Scale (PANSS). Schizophr Res 42: 231–239
Lawrence KR, Nasraway SA . (1997): Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 17: 531–537
Lindenmayer J-P, Grochowski S, Hyman RB . (1995): Five factor model of schizophrenia: replication across samples. Schizophr Res 14: 229–234
Linn MW, Gurel L, Williford WO, Overall J, Gurland B, Laughlin P, Barchiesi A . (1985): Nursing home care as an alternative to psychiatric hospitalization: a Veterans Administration cooperative study. Arch Gen Psychiatry 42: 544–551
Marsden CD, Jenner P . (1980): The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 10: 55–72
Masand PS . (2000): Side effects of antipsychotics in the elderly. J Clin Psychiatry 61 (suppl 8):43–49
Morganroth J, Brown AM, Critz S, Crumb WJ, Kunze DL, Lacerda AE, Lopez H . (1993): Variability of the QTc interval: impact on defining drug effect and low-frequency cardiac event. Am J Cardiol 72: 26B–31B
Nagatomo I, Iwagawa S, Takigawa M . (1997): Abnormal behavior of elderly people residing in institutions of medical and social welfare systems. Psychiatry Clin Neurosci 51: 53–56
Overall JE, Gorham DR . (1962): The Brief Psychiatric Rating Scale. Psychol Rep 10: 799–812
Rao AV . (1996): Fluphenazine decanoate causing atrioventricular block. Indian Heart J 48: 713–714
Salzman C . (1988): Use of benzodiazepines to control disruptive behavior in inpatients. J Clin Psychiatry 49: 13–15
Salzman C, Solomon D, Miyawaki E, Glassman R, Rood L, Flowers E, Thayer S . (1991): Parenteral lorazepam versus parenteral haloperidol for the control of psychotic disruptive behavior. J Clin Psychiatry 52: 177–180
Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD . (1999): Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 156: 79–87
Schaffer CB, Shahid A, Javaid JI, Dysken MW, Davis JM . (1982): Bioavailability of intramuscular versus oral haloperidol in schizophrenic patients. J Clin Psychopharmacol 2: 274–277
Schneider LS, Pollock VE, Lyness SA . (1990): A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 38: 553–563
Schwartz JT, Brotman AW . (1992): A clinical guide to antipsychotic drugs. Drugs 44: 981–992
Simpson GM, Cooper TB, Lee JH, Young MA . (1978): Clinical and plasma level characteristics of intramuscular and oral loxapine. Psychopharmacology 56: 225–232
Small GW, Jarvik LF . (1982): The dementia syndrome. Lancet 2: 1443–1446
Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A . (2000): Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 57: 968–976
Teitelbaum L, Ginsburg ML, Hopkins RW . (1991): Cognitive and behavioural impairment among elderly people in institutions providing different levels of care. CMAJ 144: 169–173
Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley CM Jr, Tollefson GD . (1997): Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17: 407–418
Wolthaus JED, Dingemans PMA, Schene AH, Linszen DH, Knegtering H, Holthausen EAE, Cahn W, Hijman R . (2000): Component structure of the Positive and Negative Syndrome Scale (PANSS) in patients with recent onset schizophrenia and spectrum disorders. Psychopharmacology 150: 399–403.
Wood S, Cummings JL, Hsu MA, Barclay T, Wheatley MV, Yarema KT, Schnelle JF . (2000): The use of the Neuropsychiatric Inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry 8: 75–83
Wright P, Birkett M, Meehan K, Ferchland I, David S, Alaka K, Pullen P, Brook S, Reinstein M, Breier A . (2000): A double-blind study of intramuscular olanzapine, haloperidol and placebo in acutely agitated schizophrenic patients [abstract]. Int J Neuropsychopharmacol 3 (suppl 3):S139
Acknowledgements
This work was sponsored by Eli Lilly and Company.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Meehan, K., Wang, H., David, S. et al. Comparison of Rapidly Acting Intramuscular Olanzapine, Lorazepam, and Placebo: A Double-blind, Randomized Study in Acutely Agitated Patients with Dementia. Neuropsychopharmacol 26, 494–504 (2002). https://doi.org/10.1016/S0893-133X(01)00365-7
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(01)00365-7
Keywords
This article is cited by
-
Sublingual Dexmedetomidine for Agitation Associated with Schizophrenia or Bipolar Disorder: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed
Advances in Therapy (2022)
-
Pharmacological Management of Neuropsychiatric Symptoms of Dementia
Current Treatment Options in Psychiatry (2020)
-
Subjective Versus Objective Outcomes of Antipsychotics for the Treatment of Neuropsychiatric Symptoms Associated with Dementia
CNS Drugs (2019)
-
QTc Interval Prolongation and Torsade de Pointes Associated with Second-Generation Antipsychotics and Antidepressants: A Comprehensive Review
CNS Drugs (2014)
-
A prospective study of high dose sedation for rapid tranquilisation of acute behavioural disturbance in an acute mental health unit
BMC Psychiatry (2013)
